logo
Programmed Regrowth.
Investor Pitch Deck
01The Hair Opportunity

A massive, underserved
market.

0M
Americans experience hair loss
0%of men over their lifetime
0%of men by age 35
0%of hair-loss sufferers are women
Source: American Hair Loss Association
02The Problem

Outdated, inefficient, and costly
options for hair restoration.

Invasive Surgery
$5K–$15K · specialized surgeons · weeks of painful recovery
Painful Injectables
PRP / exosomes / stem cells · needles, blood draws, in-office processing · can be painful and time-consuming
OTC Medication & Supplements
Side effects, inconsistent, slow results · high patient abandonment
The void: no standardized, clinical-grade, needle-free, 30-minute hair-restoration category exists as a topical cosmetic treatment.
03The Solution

Simplified. Standardized.
Hair Restoration.

A completely needle-free, pain-free system for medspas, clinics, salons & barbershops.

RiboHair Serum
Programmed ribosomal formulation
Sonic Vibration
+ Transdermal Delivery
Juvasonic® Device
FDA-listed Class I delivery tech
30-minute sessions
Zero patient downtime
Transdermal — no puncture
Patent-pending tech
Patent Pending US #18/467,595
04The Market Opportunity

From medical procedure to
cosmetic revenue stream.

80M sufferers — servable only through the ~1.2M medspas, hair salons & barbershops that already exist. RiboHair makes each a new revenue stream.
A Demand Problem Nobody Can Serve
80M Americans with hair loss
Entire regenerative segment (exosomes + stem cells): just $200–400M
Supply trapped in a small base of specialized clinics
Biologics: variable, unapproved (zero FDA approval), underperforming
WHY IT WINS
Programmed ribosomes outperform exosomes & stem cells - hair growth in 8 days
Standardized, consistent formulation - not variable biomass
Cosmetic + FDA-listed device - not a legal gray area
Case-series verified (Dr. Orcí & Dr. Zini); large-scale validation funded by this round
THE OPEN LANE (reach + financials, stacked)
0.5% of 80M patients = 400,000/yr
× $3,200 cycle = $1.28B uncaptured demand
5% of the ~1.2M-outlet corridor = ~61,600 locations ≈ 3.7M patients a year within reach
42,093 medspas · 131,000 barbershops · 1.06M salons — deliverable everywhere
A better-performing, standardized cosmetic, deliverable everywhere — vs. variable, unapproved biologics locked inside a handful of clinics.
10Introducing
RiboHair
A premium, needle-free, in-office hair restoration system for medspas.
Programmed ribosomal serum technology
FDA-listed Class I delivery device
30-minute sessions, zero downtime
Clinics, medspas, hair salons & barbershops
Patent Pending US #18/467,595

STARTER KIT · ONE-TIME

Everything needed to launch RiboHair treatments

Wholesale price to MedSpa, Salons, Barbershops ready to sell on day one

$3,700

STARTER KIT

The Ribohair Kit

What's included

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Juvasonic® Device

Sonic transdermal delivery · FDA-listed Class I

FDA Listed Needle-Free Serum Enhancement Technology Enhance topical absorption of cosmetic serums—without needles, pain, or compliance concerns. Juvasonic®️ uses medical-grade micro-dermabrasion and sonic vibration to temporarily disrupt the stratum corneum, allowing topical ingredients to absorb where they can work effectively.

Quantity: 1

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Juvasonic® cartridges

Sonic transdermal delivery · FDA-listed Class I

Single-Use Precision. Four Port Sizes. Enhances Topical Absorption. Designed exclusively for use with the Juvasonic®️ device, these sterile, single-use nano cartridges support enhanced topical absorption with precision-controlled serum flow. Available in four port sizes, each cartridge allows providers to match the tip to the viscosity of their selected cosmetic serum for a more controlled and efficient application.

Quantity: 12

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Dr. Pen® Microneedling Device

Ultima-M8 handpiece · adjustable depth

The benefits of cosmetic skin micro needling have been recognized for many years. Dr pen M8 uses Advanced Oscillating Vertical Needling technology with high-quality disposable tips.

Quantity: 1

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Dr. Pen® Cartridges

Ultima-M8 handpiece · adjustable depth

The Dr. Pen M8 cartridge uses ultra-thin surgical-grade stainless steel needles to safely trigger your skin's healing process. The needles pierce the skin to boost collagen, reduce wrinkles, smooth scars, and improve product absorption.

Quantity: 6

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

RiboHair Serum Vials

Programmed Ribosomes

RiboHair™️ uses programmed ribosomal technology to support the natural production of key proteins and growth factors including Keratin, FGF-7, and VEGF within hair follicle cells. Keratin supports the hair's structural strength, FGF-7 helps stimulate and prolong the follicle's growth phase, and VEGF supports the blood vessel activity that nourishes growing hair, together promoting denser, fuller, and healthier-looking hair over time.

Quantity: 4

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Capilari Factor Vials

Support Scalp Microcirculation

Capillary Growth Factor is formulated to help support scalp microcirculation and prepare the scalp environment prior to RiboHair™️ application. By promoting healthy capillary function and optimizing local tissue perfusion, it is designed to facilitate the delivery of RiboHair™️ to the hair follicle region. The formulation also contains regenerative signaling factors that are widely studied for their role in supporting tissue repair, cellular communication, and the maintenance of a healthy scalp environment.

Quantity: 4

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Lidocaine Vial

local anesthetic

Lidocaine is a powerful local anesthetic that works by temporarily blocking nerve signals in your body.

Quantity: 1

05Market Tailwinds

The timing is on our side.

$0.0B
US medspa market by 2034
From $7.4B in 2025 · 17.3% CAGR - This channel
0
Medspas in CA · FL · TX
~33% of the US market - First markets we’re targeting
Sources: Precedence Research · DoctorsListsHQ
06The Consumer Shift

Consumers are paying more —
and earlier.

0%
of US consumers spent more on cosmetic procedures in 2024 than 2023
0%
of Gen Z spent more on cosmetic procedures year-over-year
0%
rank healthy aging as a top priority globally
“Better appearance” jumped from #6 to #3 wellness priority for Gen Z in a single year.
Source: McKinsey Future of Wellness 2025
07Manufacturer's Lens

Just 400 of 42,093 medspas
generate $38.4M.

4 sales reps × 25 medspas/quarter each → 400 medspas/year
1 active account = $96K/yr at run-rate Year 1: 400 accounts onboarded (ramping) → $17.29M revenue
Base Case
$38.4M
400 medspas
Year-1 build → Year-2 steady
5% of Medspas
~$202M
~2,100 qualified aesthetic channel
Realistic mid-term penetration
5% of Full Channel
~$5.9B
~61,600 + salons & barbershops
Full distribution expansion
The MedSpa profits from day one (Owner's Lens); RIBODEX compounds across accounts (Manufacturer's Lens) — one transaction pays both.
08B2B Unit Economics

Manufacturer-direct,
72.5% margins.

Starter Kit · One-Time
Wholesale price to MedSpa$3,700
Hardware + product COGS$2,238
Gross profit / bundle$0
39.5% gross margin
Kit COGS: Juvasonic $1,250 · 12 cartridges $150 · Dr. Pen $160 · 6 cartridges $18 · 6 RiboHair $330 · 6 Capilari $330
Recurring Reorder Flywheel
Wholesale serum price / vial$400
Consolidated session COGS$110
Gross profit / vial$0
72.5% gross margin
Session COGS: RiboHair serum $55 · Capilari $55
09MedSpa Partner Value Proposition

The MedSpa profits from the
RiboHair kit.

$3,700
Starter kit invested
$4,800
Starter kit revenue
6 treatments × $800
+$1,100
Net cash flow
profitable from patient 1
Per Patient · 4-Treatment Cycle
Patient pays MedSpa$3,200
MedSpa pays RIBODEX$1,600
MedSpa gross profit (50%)$1,600
Operational Superiority
No centrifuge, blood draws, or medical waste
Administered by aestheticians — no nurses, MDs, or high-salary staff
30-min treatment = high throughput
10Per-Chair Capacity Ceiling

Owner's Lens — what one
active chair can generate.

9am–6pm · 30-min treatment + 10-min reset · 13 slots × 1 chair = 13/day · at 50% utilization = 6 treatments/day
RIBODEX
Revenue at one chair's max capacity
Daily
Monthly
Annual
Vials sold
6
132
1,584
Revenue
$2,400
$52,800
$633,600
Gross profit
$1,740
$38,280
$459,360
72.5% gross margin
MEDSPA
One chair · 50% utilization
Daily
Monthly
Annual
Treatments
6
132
1,584
Revenue
$4,800
$105,600
$1.27M
Gross profit
$2,400
$52,800
$633,600
50% gross margin
Base case = 5 patient-starts/mo = $96K/yr per account. This is the capacity ceiling one active chair can grow into
11Competitive Landscape

Standardized precision without
clinical constraints.

RIBOHAIR
PRP
EXOSOME
STEM CELL
SURGICAL
Full-cycle patient cost
$3,200
$2,600
~$2K–$6K
$6K–$12K
$5K–$15K
Primary delivery
Needle-free sonic
Needles
Needles
Needles
Follicular graft
Patient downtime
0 minutes
1–2 days
1–2 days
2–3 days
1–2 weeks
Active yield
100% standardized
Variable biomass
Variable batch
Variable batch
N/A
Staffing need
Aesthetician
Nurse / PA / MD
Nurse / PA / MD
Nurse / PA / MD
Surgeon
Infrastructure
Standard spa room
Centrifuge + labs
Refrig. + labs
Refrig. + labs
Surgical suite
12Sales Rep Execution Model

Predictable ramps,
high accountability.

Quota: 25 new accounts per quarter → 100 medspas per rep, annually. Month 1 (-$1,169) onboarding investment, recovered by month 2.
Through Month 2
8
cumulative accounts
+$13,836 turns positive
Through Month 6
44
cumulative accounts
+$416,628 cumulative net profit
Through Month 12
100
cumulative accounts
+$2,735,300 cumulative net profit
Per Sales Rep · Year 1
100
active medspas
9,880
vials sold
$4.32M
gross revenue
$2.74M
net profit (63.3%)
13Financial Scale — Year 1

A high-velocity recurring-
revenue engine.

All 4 sales reps combined · kit + recurring revenue
$17.29M
Total revenue
$10.94M
Net profit (63.3%)
$12.05M
Gross profit
39,520
Vials sold
Cumulative recurring revenue — Year 1
Month 1Month 12
$0.0M cumulative
December run-rate $2.91M / month · 72.5% recurring gross margin
14Year 1 → Year 2 Scale

From ramp to steady-state
run-rate.

Year 1
Year 2
Growth
Total revenue
$17.29M
$38.40M
+122.1%
Gross profit
$12.05M
$27.84M
+131.1%
Net profit
$10.94M
$25.68M
+134.7%
Vials sold
39,520
96,000
+142.9%
Corporate net margin
63.3%
66.9%
+3.6 pts
Year 2 = 400 active medspas at steady state — pure recurring consumption, no kit costs. Year-2 margin is contribution after direct sales cost; full corporate opex is funded from the raise.
15Beauty Meets Longevity

Hair is the next longevity
category.

$0T
global longevity economy by 2030 (UBS)
the wave RIBODEX rides
<0%
of skincare launches used longevity positioning in 2024
Euromonitor
0×
growth in longevity beauty ingredient mentions, Aug 2024 → Aug 2025
Launch Metrics
Hair care flagged as the next longevity category — L'Oréal, Estée Lauder & Beiersdorf all launched longevity lines in 2024–2025.
RiboHair is the wedge. RIBODEX is the platform. Longevity is the wave.
16Additional Opportunity

A $9B+ surgical market — as a
competitor or a complement.

Hair transplants are a ~$9–11B global market growing toward ~$25–50B by 2034. RiboHair captures value on both sides.
Path A
The Alternative
Transplants cost $6,000–$15,000 per procedure
Surgical · weeks of recovery · surgeon required
RiboHair: $3,200, needle-free, no surgery, no downtime
Converts price- & pain-sensitive patients who avoid surgery
Path B
The Complement
Adjunct to transplant — post-surgical recovery & follicle activation
Adds a recurring cosmetic revenue stream to every surgical practice
Turns a one-time surgery into an ongoing relationship
Clinical validation of the adjunct funded by this round
Whether a patient avoids surgery or elects it, RiboHair is in the transaction — a standalone alternative and an add-on to the surgical market.
[
THE TEAM
]

The people behind Ribodex

Clinical case studies from our investigative physicians. Results shown after a four-treatment cycle.

Founder & CEO, Medolife Corporation (2007-present)

Inventor - programmed-ribosome technology (USPTO #18/467,595)

CSO - BioAlliance Holdings · Peptigenix · Ribodex

18+ years in peptide & molecular-delivery R&D

Dr. Arthur Mikaelian

CO-FOUNDER & INVENTOR

Inventor of RIBODEX's programmed-ribosome technology and a biotechnology founder with nearly two decades building peptide and molecular-delivery research programs. As Founder & CEO of Medolife Corporation (2007-present), he has led peptide-based therapeutic research across oncology and related fields, built international research partnerships, and directed programs tied to patented and patent-pending molecular-delivery technologies. He is also founder of Mikaelian Resonance Technology and serves as Chief Scientific Officer across BioAlliance Holdings, Peptigenix LLC, and Ribodex LLC.

Founder & CEO, Borden Industries

Co-Founder / President / COO, Switch Communications (exit 2010)

Early investor — TruFusion · Reebok One

Michael Borden

CO-FOUNDER & INVESTOR

A veteran operator and investor who turns disruptive technologies into scalable, high-value businesses. Founder & CEO of Borden Industries, leading strategy, capital formation, and partnerships across industrial manufacturing, biotechnology, nuclear power (Valar Atomics), and defense (Knightwerx). A Las Vegas native, he was previously Co-Founder, President & COO of Switch Communications (exit 2010), with early positions in TruFusion and Reebok One. Served on the board of Habitat for Humanity for 12 years (8 as Chairman); Advisory Chair for Mondays Dark.

20+ Years Surgical Experience

Regenerative Medicine Expert

Founder of Advanced Nasal Therapies

Founder of Advanced Nasal Therapies

Dr. Gonzalo Jimenez-Orcí

INVESTIGATIVE PHYSICIAN & CLINICAL ADVISOR

A physician and regenerative-medicine researcher with 15+ years in stem-cell and exosome clinical research, a pioneer of stem-cell therapy clinical research in Mexico. Board-certified in Otolaryngology, on staff at Angeles Hospital, Tijuana; member of the College and Council of Regenerative Medicine and Cellular Therapy in Mexico; on the hospital IRB since 2008; clinical-trial administrator trained through UC San Diego (2012). Currently Chief Medical Director, Immunotherapy Wellness Center, Tijuana. 2019 Leadership Award.

PhD, Cell & Developmental Biology - Vanderbilt

Founder, Mighty Ventures (translational life sciences)

Former CSO, Tikun Olam USA · Board Director, Flora Growth (Nasdaq)

NIH clinical-trial certified · Congressional recognition

Dr. Annabelle Manalo-Morgan, PhD

SCIENTIFIC ADVISOR & INVESTIGATIVE RESEARCHER

A cell and developmental biologist and translational-medicine founder, serving as a Scientific Advisor and investigative researcher on RIBODEX's programmed-ribosome technology. PhD in Cell & Developmental Biology from Vanderbilt (cardiac development / chemotherapy cardiotoxicity); graduate training in neuroscience at Georgetown; NIH clinical-trial certified. Founder of Mighty Ventures; former CSO of Tikun Olam USA; Board Director & Lead Scientific Officer of Nasdaq-listed Flora Growth Corp. Launching NFL-concussion and women's-fertility trials Q1 2026. Recognized by the U.S. Congress for a scientific breakthrough; ForbesBooks bestselling author (Mighty Flower, 2023).

Hair Surgeon & Trichologist

Aesthetic Medicine Doctor

Hair Restoration Specialist

Founder, Procapelli Clinic

Dr. Danessa Zini

SCIENTIFIC ADVISOR & INVESTIGATIVE RESEARCHER

Dr. Zini: observed activation of dormant follicles and stimulation of existing hair in her cases, as early as two weeks (image clearance pending). “RiboHair is a more targeted and simpler procedure with faster results. Does not require blood extraction or handling, which reduces stress and anxiety in patients.” - Dr. Danessa Zini

Executive Vice President, Medolife Corporation

Grant Mikaelian

Executive Vice President, Medolife Corporation

Grant Mikaelian brings a thoughtful, hands-on approach to business administration, operations, and project coordination across biotechnology and healthcare initiatives. He works closely with teams across the organization to improve communication, solve challenges, and help ensure each project moves forward with the clarity, care, and accountability patients, partners, and stakeholders deserve.

Micro & Cellular Biologist

Programmed-Ribosome Researcher

Scientific Testing Lead

Eduard Sahakyan

Micro and Cellular Biologist

Eduard Sahakyan is a Micro and Cellular Biologist and a day-one founding team member at RiboDex. Dedicated to advanced biotechnology, Eduard leads the rigorous scientific testing of our topical aesthetic products. His work focuses on utilizing programmed ribosomes for targeted cell therapy, translating complex cellular science into breakthrough cosmetic solutions for hair growth and skin rejuvenation

Founder & CEO, Blue Scorpion

Business, Sales & Company Building

FDA-listed OTC · Issued NDC · TruShield Certified

Harut Tovmasyan

Business Development & Go-to-Market

Harut Tovmasyan is a versatile operator with a strong foundation in business, sales, and company building the kind of founder who does whatever the task requires to get it done. He leads Blue Scorpion®, a homeopathic biotech company, he brought to market the first-of-its-kind blue-scorpion-venom-based OTC medicine FDA-listed with an issued National Drug Code and TruShield Certified and built global awareness for the brand and product. He leads RiboHair's business development and go-to-market strategy.

Founder of hueco.it

Founder of Aura Studios

Blue Scorpion Head Designer & Developer

Diego Cajaza

Creative Director, Motion Designer & Developer

With over two decades of experience, he is a multidisciplinary creative and art director, motion designer, 3D artist, product innovator, and full-stack developer working at the intersection of design, technology, and storytelling. His work blends strategic thinking, advanced visual direction, cinematic motion, immersive digital experiences, and technical development to transform ideas into powerful brand ecosystems. From high-end 3D visuals and motion design to branding, interactive platforms, and product experiences, he creates work that is bold, emotionally engaging, and visually distinctive. Every project is approached as a complete creative system, where aesthetics, functionality, innovation, and narrative come together to build memorable experiences that connect with people and elevate brands.

17Infrastructure & The Ask
$0M
EQUITY ROUND
Company Assets · real assets behind the raise
$2.5M+capital deployed ahead of this round
$1.7Mbuilding owned, lab being built out (inside the $2.5M)
$2.5Minventory on hand (retail value — shown separately)
Use of Funds
Sales-force acceleration
Direct B2B across FL · CA · TX
Supply-chain capitalization
Wholesale serum raw materials, Juvasonic & Dr. Pen units for better margins
Studies
Hair-follicle activation & hair-transplant recovery study
Milestone to Next Round
400 active accounts · $38.4M annual run-rate

RIBODEX

AUTHORIZED ACCESS ONLY
ENTER CREDENTIALS
PROTECTED CONTENT — 2026